Group 1 - The extension of the US-China tariff truce by 90 days has led to a bullish trend in Asian stock markets, including India, where corporate earnings are showing signs of recovery and retail investors are continuously injecting funds through mutual funds [1] - The domestic consumption market in India is showing optimistic performance, supported by low inflation, abundant monsoon rainfall, and a personal tax relief policy worth 1 trillion rupees, which collectively boost the consumer goods sector [1] - Motilal Oswal Financial Services predicts a 10% increase in earnings per share for Nifty 50 index constituents this fiscal year, significantly higher than the previous fiscal year's growth of only 1% [1] Group 2 - The domestic market has become a stabilizing factor for Indian pharmaceutical companies, with local sales showing resilience amid uncertainties in the US market due to tariffs [1] - In July, the sales of domestic pharmaceuticals in India grew by 7.9% year-on-year, marking the second-highest growth rate in six months [1] - Companies like Glenmark, Sun Pharma, Alkem, Torrent Pharma, and Dr. Reddy's have outperformed the market average, while Cipla and Lupin lag behind [2] Group 3 - The National Commodity and Derivatives Exchange (NCDEX) has received preliminary approval from market regulators to conduct stock derivatives trading, positioning itself as a competitor to major players like NSE and BSE [3] - Despite a market decline in July due to tariff concerns and weak corporate earnings, Indian retail investors injected a record 427 billion rupees (approximately 4.9 billion USD) into equity funds [3] - The contrasting trend of domestic investors becoming market stabilizers while foreign funds experienced a net outflow of about 3 billion USD highlights the growing importance of local investors in providing support during market downturns [3]